共 50 条
- [31] Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 195 - 202Wolff, Antonio C.Lazar, Ann A.Bondarenko, IgorGarin, August M.Brincat, StephenChow, LouisSun, YanNeskovic-Konstantinovic, ZoraGuimaraes, Rodrigo C.Fumoleau, PierreChan, ArleneHachemi, SoulefStrahs, AndrewCincotta, MariaBerkenblit, AnnaKrygowski, MizueKang, Lih LisaMoore, LaurenceHayes, Daniel F.
- [32] Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer - A prospective, randomized, phase III studyAMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (03): : 317 - 322Milla-Santos, AMilla, LPortella, JRallo, LPons, MRodes, ECasanovas, JPuig-Gali, M
- [33] The efficacy and safety of neoadjuvant chemotherapy ± letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trialBREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) : 853 - 861Mohammadianpanah, MohammadAshouri, YaghoubHoseini, SareAmadloo, NiloofarTalei, AbdolrasoulTahmasebi, SedighehNasrolahi, HamidMosalaei, AhmadOmidvari, ShapourAnsari, MansourMosleh-Shirazi, Mohammad Amin
- [34] The efficacy and safety of neoadjuvant chemotherapy +/− letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trialBreast Cancer Research and Treatment, 2012, 132 : 853 - 861Mohammad MohammadianpanahYaghoub AshouriSare HoseiniNiloofar AmadlooAbdolrasoul TaleiSedigheh TahmasebiHamid NasrolahiAhmad MosalaeiShapour OmidvariMansour AnsariMohammad Amin Mosleh-Shirazi
- [35] Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival modelHealth Economics Review, 13Ali DarvishiRajabali DaroudiAli Akbar Fazaeli
- [36] Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) StudyJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 1045 - +Martin, MiguelLoibl, Sibyllevon Minckwitz, GunterMorales, SerafinMartinez, NoeliaGuerrero, AngelAnton, AntonioAktas, BahriyeSchoenegg, WinfriedMunoz, MontserratAngel Garcia-Saenz, JoseGil, MiguelRamos, ManuelMargeli, MireiaCarrasco, EvaLiedtke, CorneliaWachsmann, GrischaMehta, KeyurDe la Haba-Rodriguez, Juan R.
- [37] Phase II Parallel Group Study Showing Comparable Efficacy Between Premenopausal Metastatic Breast Cancer Patients Treated With Letrozole Plus Goserelin and Postmenopausal Patients Treated With Letrozole Alone As First-Line Hormone TherapyJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2705 - 2711Park, In HaeRo, JungsilLee, Keun SeokKim, Eun-AKwon, YoungmeeNam, Byoung-HoJung, So-YounLee, SeeyounKim, Seok WonKang, Han Sung
- [38] Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: Evidence from metastatic subgroups and a test of functional abilityONCOLOGIST, 2004, 9 (05): : 489 - 496Mouridsen, HSun, YGershanovich, MPerez-Carrion, RBecquart, DChaudri-Ross, HALang, R
- [39] Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 studyCANCER MEDICINE, 2020, 9 (14): : 4929 - 4940Takahashi, MasatoMasuda, NorikazuNishimura, ReikiInoue, KenichiOhno, ShinjiIwata, HirojiHashigaki, SatoshiMuramatsu, YasuakiUmeyama, YoshikoToi, Masakazu
- [40] First-line therapy with letrozole (Femara®) for advanced breast cancer prolongs time to worsening of Karnofsky Performance Status compared with tamoxifen.BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 291 - 291Mouridsen, HSun, YGershanovich, MPerez-Carrion, RBecquart, DChaudri-Ross, HALang, RBrady, CDugan, M